相关实验视频

Updated: Jan 13, 2026

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

向AASS减轻神经毒性,并改善神经元功能在星细胞模型的依赖

Imke M E Schuurmans^1,2,3, Udo Engelke^4,3, Muna Abedrabbo^5,3

¹Radboud University Medical Center, Amalia Children's Hospital, Department of Pediatrics, 6500 HB Nijmegen, the Netherlands.

Molecular therapy. Nucleic acids

|October 29, 2025

概括

甲素依赖性 (PDE) 是一种罕见的神经代谢疾病. 用反感性寡核酸 (AONs) 向α-氨基基半合酶 (AASS) 显示出减少有毒代谢物和治疗PDE的希望.

科学领域:

神经科学是一个神经科学.
遗传学遗传学是一个
代谢障碍代谢障碍代谢障碍

背景情况:

皮里多克素依赖性 (PDE) 是一种罕见的神经代谢疾病,由ALDH7A1变体引起,导致神经毒性代谢物积累.
目前用于PDE的治疗方法提供了部分症状缓解,但不能治愈,需要新的治疗策略.
星球细胞在大脑代谢平衡中起着至关重要的作用,是ALDH7A1.1.的主要来源.

研究的目的:

使用患者衍生天体细胞调查PDE的潜在机制.
确定和验证PDE的潜在治疗点.
在PDE的细胞模型中探索AON治疗的疗效.

主要方法:

患者衍生的人类诱导多能干细胞 (hiPSCs) 的生成和分化为星球细胞.
代谢和RNA测序分析以表征PDE天体细胞表型.
通过CRISPR-Cas9基因编辑和反感性寡核酸 (AON) 处理以准AASS.

主要成果:

在PDE天体细胞中,PDE生物标志物升高,氧化应激增加,DNA氧化,ROS水平和脂质过氧化.
线粒体功能障碍是由PDE星体细胞中氧气消耗率失调的指标.
使用CRISPR-Cas9或AONs降低AASS的调节减轻了PDE星球细胞中的病理表型.

结论:

氨酸的催化作用有助于PDE的发病.
用AON针对AASS是一种有前途的治疗策略,可以减少PDE中神经毒性代谢物积累.
这项研究为开发针对PDE和其他罕见神经代谢疾病的向治疗提供了基础.

关键词:

这是一个AASSASS.在ALDH7A1中,MT:寡核酸:治疗方法和应用.反感的寡核化物.星球细胞是星球细胞.人类疾病建模模型诱导多能干细胞的诱导干细胞.lysine 的代谢障碍 lysine 的代谢障碍代谢性疾病是代谢性疾病.

更多相关视频

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...